Pursuing novel therapeutics targeting NASH/MASH
Madrigal is a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), also known as metabolic dysfunction associated steatohepatitis (MASH). Our first therapy was granted accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of adults with NASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) and is being studied in a Phase 3 trial for the treatment of NASH with compensated cirrhosis.
NEWS
March 11, 2025
Madrigal Appoints Jacqualyn A. Fouse, Ph.D. to Its Board of DirectorsFebruary 26, 2025
Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces New Two-Year Data Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH CirrhosisPRESS RELEASES >
EVENTS
March 04, 2025
TD Cowen 45th Annual Health Care ConferenceListen to Webcast
February 26, 2025
Q4 2024 Earnings CallListen to Webcast